teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 44 Projects Releases Packages Wiki Activity Actions 418
teleo-codex/entities/health/orbicular-pharmaceutical-technologies.md
Teleo Agents 1b0cc94a3b
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
vida: extract claims from 2026-04-21-apotex-fda-tentative-approval-generic-semaglutide 
- Source: inbox/queue/2026-04-21-apotex-fda-tentative-approval-generic-semaglutide.md
- Domain: health
- Claims: 0, Entities: 2
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
2026-04-21 04:49:34 +00:00

710 B
Raw Blame History

type entity_type name domain status founded headquarters website tags
entity company Orbicular Pharmaceutical Technologies health active null null null
generic-pharmaceuticals
semaglutide
GLP-1
formulation

Orbicular Pharmaceutical Technologies

Pharmaceutical formulation development company.

Overview

Orbicular Pharmaceutical Technologies partnered with Apotex on the development of generic semaglutide injection that received first US FDA tentative approval.

Timeline

  • 2026-04-10 — Partnership with Apotex received first US FDA tentative approval for generic semaglutide injection (ANDA). Orbicular provided formulation development expertise for the generic version.